ganaxolone for CDKL5
Selected indexed studies
- Ganaxolone (Ztalmy) for CDKL5 deficiency disorder. (Med Lett Drugs Ther, 2024) [PMID:39137179]
- Ganaxolone, an approved therapy for CDKL5-Deficiency Disorder, is an inhibitor of PTP1B. (bioRxiv, 2025) [PMID:41279528]
- ** (, 2025) [PMID:40310960]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial. (2022) pubmed
- Ganaxolone (Ztalmy) for CDKL5 deficiency disorder. (2024) pubmed
- Ganaxolone, an approved therapy for CDKL5-Deficiency Disorder, is an inhibitor of PTP1B. (2025) pubmed
- PMID:40310960 (2025) pubmed
- Ganaxolone for management of seizures associated with CDKL5 deficiency disorder. (2023) pubmed
- Ganaxolone: A New Treatment for CDKL5 Deficiency Disorder. (2022) pubmed
- Effects of ganaxolone on non-seizure outcomes in CDKL5 Deficiency Disorder: Double-blind placebo-controlled randomized trial. (2024) pubmed
- Ganaxolone: First Approval. (2022) pubmed
- Novel Medication Ganaxolone for Seizure Disorders. (2025) pubmed
- CDKL5 Deficiency Disorder. (1993) pubmed